Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.
Veeru Kasivisvanathan explains the background and clinical implications of the PRECISION trial, which tested whether using multiparametric MRI with a targeted biopsy was noninferior to standard transrectal ultrasonography–guided biopsy in the detection of clinically significant prostate cancer.
Alison Birtle discusses the rationale for adjuvant chemotherapy for upper tract urothelial cancer (UTUC), the POUT trial and its practice-changing implications for treatment of UTUC.
Metformin does not improve progression-free survival for patients without diabetes who require chemoradiotherapy for stage IIIA or IIIB non-small-cell lung cancer, suggests research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.
Brian Baumann presents their comparative analysis of the adverse event profiles of proton and photon radiotherapy in nonmetastatic patients receiving chemoradiotherapy with curative intent for various solid tumors, including lung cancer (5:28).
Subgroup analysis of the IMmotion151 trial suggests improved survival with first-line atezolizumab plus bevacizumab versus sunitinib for locally advanced or metastatic renal cell carcinoma patients with sarcomatoid differentiation.
Using expanded criteria for clinical trial inclusion could lead to nearly twice as many patients with advanced non-small-cell lung cancer being eligible for participation compared with traditional criteria, participants at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, heard.
Adding bevacizumab to gemcitabine plus cisplatin chemotherapy does not improve overall survival when used as first-line therapy for metastatic urothelial carcinoma, show results of the phase III CALGB 90601 study.
Veeru Kasivisvanathan explains the background and clinical implications of the PRECISION trial, which tested whether using multiparametric MRI with a targeted biopsy was noninferior to standard transrectal ultrasonography–guided biopsy in the detection of clinically significant prostate cancer.
Meet the Editorial Board
Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.
Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance
Register today and receive updates directly to your inbox! Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology. Already registered? Log in now to unlock your access.
